

1 **DIABETIC RETINOPATHY CLINICAL RESEARCH NETWORK**

2
3 **ORGANIZATIONAL STRUCTURE**

4
5 **Version 7.0 – January 4, 2012**

6
7
8 **A. Introduction**

9 The permanent central units of the project include the Coordinating Center and the Operations
10 Center.

11
12 The committee structure includes an Executive Committee and the Operations Group, as well as
13 two National Eye Institute appointed committees: the Data and Safety Monitoring Committee
14 (DSMC), which is advisory to the Coordinating Center and the National Eye Institute (NEI), and
15 an External Protocol Review Committee, which is advisory to the NEI. Sub-committees will be
16 created by the Executive Committee as necessary.

17
18 The Executive Committee is responsible for providing scientific oversight of Network activities,
19 including scientific oversight of both the Operations Center and the Coordinating Center as well
20 as oversight of Network policies within the confines of the NIH terms and conditions for
21 cooperative agreements. The Executive Committee can be considered analogous but not
22 synonymous to a board of directors with respect to making policy decisions that are necessary
23 for the scientific aspects of the Network, providing advice regarding Operations Group activities,
24 selecting the Network Chair (subject to approval of the National Eye Institute) and Vice Chairs,
25 and providing members who serve as part of periodic review of the Coordinating Center and
26 Operations Center. The Operations Group is responsible for implementing the daily scientific
27 operations of the Network and providing recommendations to be approved by the Executive
28 Committee, analogous to senior officers (e.g., chief executive officer, chief operations officer,
29 and other key positions) of a company. The Network investigators serve in an analogous role as
30 “employee shareholders” of the Network, whose participation are needed to implement
31 protocols; for example, implementation of protocols recommended by the Executive Committee
32 and major publications of Network protocol results can occur only with buy-in and enthusiasm of
33 Network clinical sites.

34
35 **B. Central Units**

36 **I. Coordinating Center**

37 The DRCR.net Coordinating Center is located at the Jaeb Center for Health Research in Tampa,
38 Florida. Specific responsibilities of the Coordinating Center include:

- 39 • Solicit ideas for new studies from investigators
- 40 • Assist the Operations Group with the development of study protocols and the protocol
41 development committees
- 42 • Obtain and maintain INDs and IDEs

- 43 • Develop study documents such as protocols, operating procedures manuals, and data
44 collection forms
- 45 • Maintain version control of all protocols, study documents, publications, presentations, and
46 the like
- 47 • Coordinate and monitor the conduct of study protocols
- 48 • Develop and implement a data management system capable of supporting multiple projects
- 49 • Develop and maintain a multi-functional private website for use by the Coordinating Center,
50 clinical centers, retinal imaging reading centers, Operations Center, and committee members
- 51 • Develop and maintain a website for public use
- 52 • Develop procedures for patient enrollment and randomization
- 53 • Develop and implement a system for adverse event reporting
- 54 • Develop and implement a quality assurance program that includes training and certification
55 of clinic staff, monitoring of adherence to the protocol, reporting of quality control data,
56 validation of collected data, assessments of retinal imaging reading center(s), and assessment
57 of drug packaging and labeling
- 58 • Coordinate the selection process of clinical centers in conjunction with the Network Chair
- 59 • Develop procedures and materials for certification of clinical centers and associated staff
- 60 • Develop systems to assist the clinical centers in maintaining a high rate of patient retention
- 61 • Develop and maintain a system to facilitate communication between the central units, clinical
62 centers, and committees
- 63 • Develop and maintain a system for drug distribution and accountability
- 64 • Coordinate site visits, prepare site visit agendas, and prepare site visit reports
- 65 • Develop and maintain a system for semiannual collection, review, and reporting of financial
66 disclosures for investigators, coordinators, and other key personnel as defined in the
67 Network's Financial Disclosure policy
- 68 • Develop a system, if needed, for integration of a central laboratory into the project
- 69 • Develop and oversee implementation of subcontracts with clinical sites to participate in
70 DRCR Network protocols
- 71 • Develop contracts with other centralized resource groups utilized in DRCR Network
72 protocols, such as imaging reading centers for grading and transmission of imaging data to
73 the Coordinating Center
- 74 • Develops contracts with industry collaborators following the DRCR Network's Industry
75 Collaboration Guidelines
- 76 • Develops processes to accept unrestricted gifts within regulations and approval of the
77 National Eye Institute
- 78 • Implement subcontracts with the participating clinical centers

- 79 • Develop materials for IRB submissions by the clinical centers
- 80 • Track IRB approvals and expirations
- 81 • Develop study close-out procedures and materials
- 82 • Develop statistical analysis plans
- 83 • Coordinate the preparation and publication of study manuscripts, including drafting the initial
- 84 manuscript draft
- 85 • Conduct data analyses for Data and Safety Monitoring Committee review as well as for
- 86 manuscripts, abstracts, presentations, and ancillary studies
- 87 • Coordinate activities with the Operations Center, Executive Committee, Operations Group
- 88 and any other committees
- 89 • Coordinate activities of the Data and Safety Monitoring Committee
- 90 • Arrange conference calls
- 91 • Arrange meetings, including semiannual Protocol Review Committee/Operations Group
- 92 Quality Control meetings, semiannual Coordinator/Investigator meetings, semiannual
- 93 Executive Committee/Protocol Prioritization & Planning meetings, semiannual Data and
- 94 Safety Monitoring Committee meetings, and Protocol Development Committee meetings
- 95 • Develop and disseminate agendas and summaries of committee conference calls and
- 96 meetings in coordination with the Operations Center
- 97 • Assist with communication with NIH, JDRF, regulatory agencies, and the public
- 98 • Develop clinical center budgets in conjunction with the Executive Committee
- 99 • Develop and maintain directory of project personnel
- 100 • Maintain direct contact with study participants

101 **II. Network Chair and Operations Center**

102 The Network Chair works closely with, but independently of, the Coordinating Center for the
 103 following specific responsibilities:

- 104
- 105
- 106 • Assume overall scientific responsibility and direction for Network protocols
- 107 • Chair the Operations Group to manage day-to-day Network scientific activities
- 108 • Provide input and assist with preparation of all manuscripts, abstracts, and slide set
- 109 presentations
- 110 • Provide initial review of Network financial disclosures with the PI of the Coordinating
- 111 Center or senior member of the Coordinating Center designated by the PI to determine if a
- 112 financial conflict exists per the Network's policies based on disclosures (subject to review
- 113 and final decision of the Executive Committee) and to recommend plans to manage any
- 114 financial conflicts (subject to review and final decision of the Executive Committee)
- 115 • Serve as spokesperson of the Network to the public

- 116 • Chair monthly investigator calls
- 117 • Represent the Network with regulatory agencies such as the FDA
- 118 • Assist the Coordinating Center with communication with IRBs when ophthalmic expertise is
119 needed
- 120 • Assist and back-up Protocol Chairs
- 121 • Participate with the Coordinating Center in coordination of activities between the Network
122 and the NEI
- 123 • Assist with communication with NIH, JDRF, regulatory agencies, and the public
- 124 • Participate and serve as spokesperson in coordination of activities between the Network and
125 industry (for-profit) sponsors, other not-for-profit sponsors (e.g., Juvenile Diabetes Research
126 Foundation, International), and third party payers
- 127 • Identify potential funding sources
- 128 • Assist the Coordinating Center with oversight of the Network annual budget including
129 determining amounts available for new protocols
- 130 • Review and approve new site/investigator Network applications
- 131 • Communicate with international sites interested in participating in the Network
- 132 • Work with the Coordinating Center to coordinate and back-up the activities of the Vice-
133 Chair(s) and other funded “working” positions (e.g., investigators funded to work on protocol
134 development or manuscripts or presentations)
- 135 • Provide support to other researchers desiring to use methodology developed for Network
136 operations or protocols, such as financial disclosure procedures and competing studies
137 procedures
- 138 • Review of ‘competing studies’ proposals, with regard to impact on existing or planned
139 DRCR.net protocols
- 140 • Serve as an ex officio representative to the Data and Safety Monitoring Committee and the
141 External Protocol Concept Review Committee as needed
- 142 • Oversee consultant expertise when needed for a specific protocol for which expertise is not
143 available within the Network.

144
145 The Network Chair will be selected through solicitation of Network participants. The Network
146 Chair will serve no more than two five-year terms coincident with the funding cycle of the
147 DRCR.net Operations Center. (Refer to separate document, Process for Selection of DRCR.net
148 Chair, for more details.)

149
150
151 **III. Network Vice-Chair(s)**

152 The Network Vice-Chair(s) will work closely with the Network Chair and Coordinating Center
153 to oversee site monitoring and protocol monitoring, develop and maintain quality assurance, and
154 backup the Network Chair and Protocol Chairs when needed. Each Vice-Chair works with his or

155 her Coordinating Center Protocol Monitor and is responsible for maintaining communication
156 with their designated sites' investigators to resolve issues, encourage enrollment, and discuss
157 other protocol- or site-related issues. For a complete listing of responsibilities, see Operations
158 Group.

159
160 Up to three Network Vice-Chair(s) may serve the Network at any given time. Network Vice-
161 Chairs will be selected through solicitation of Network investigators. Each Network Vice-Chair
162 provides at least 10% effort for Network-related activities. The Vice-Chair(s) will serve one-year
163 renewable terms, up to three years with the exception of the inaugural Vice-chairs. For the
164 inaugural Vice-Chairs, at least one will rotate off after years two, three, and four, so one member
165 will have the opportunity to serve as Vice-Chair for two years and one member for up to four
166 years. (Refer to separate document, Process for Selection of Network Vice-Chair, for more
167 details).

168

169 **IV. Other Network Investigator Positions(s)**

170 The Network creates other Investigator Positions as needed, for example, for manuscript and
171 protocol development. Investigator members serving in these positions will serve one-year terms
172 renewable throughout each NIH grant period. Members serving in these positions will work
173 closely with the Network Chair and Coordinating Center for new protocol development and
174 implementation and manuscript preparation with the following specific responsibilities:

- 175 • Conduct initial review of submitted protocol concepts for discussion with the Operations
176 Group
- 177 • Work with the Protocol Chairs, Network Chair, Coordinating Center staff, and Protocol
178 Development Committees on protocol development
- 179 • Develop drafts of new protocols
- 180 • Review data to be collected for each protocol
- 181 • Assist Coordinating Center in developing materials for a protocol, including Procedure
182 Manual, certification materials including Q and A, case report forms (including review of
183 website application, and site budget
- 184 • Review of data to be collected in network protocols, including case report forms, imaging
185 (e.g., OCT, photos, FA) and other types of data collection
- 186 • Conduct initial review of submitted ancillary study concepts from investigators, research the
187 topic when needed, and decide on degree of merit and priority for recommendation to the
188 Executive Committee
- 189 • Work with the Coordinating Center staff to develop and evaluate manuscript proposals
- 190 • Work with the Coordinating Center staff to develop, review, refine analyses for the proposals
- 191 • Review manuscript outlines, initial data, and manuscript drafts
- 192 • Write parts of manuscripts including literature reviews
- 193 • Draft responses to journal reviewer comments

- 194 • Development of analyses, abstracts, and final presentation materials for meeting
195 presentations
- 196 • Provide oversight to meeting presentations
- 197 • Assist the Coordinating Center and Operations Group members with manuscript
198 writing/reviewing
- 199

200 **C. Clinical Sites**

201 The clinical sites will be responsible for carrying out the common study protocols. A
202 participating clinical site must have at least one individual who meets criteria to be a Network
203 Investigator (refer to a separate document, DRCR Site Requirements, for additional information).
204 One investigator at the site must be designated as the principal investigator, who will have
205 overall responsibility for all study-related activities and all data collection at the center (refer to a
206 separate document, Responsibilities of DRCR.net Principal Investigators for Research Data
207 Integrity, for additional information). Additional clinical site staff include co-investigators, clinic
208 coordinators, and other personnel as needed for the project. Appropriate backup must be
209 available for all positions. Clinical site investigators will have an active role in all aspects of
210 the project including protocol development, data analyses, and publication of results.
211

212 **D. Protocol Chairs and Protocol Development Committees**

213 Each protocol, including primary protocols and ancillary studies, will have a designated Protocol
214 Chair or co-Chairs. Multi-phase protocols may have a separate protocol chair for each phase.
215 Each Chair will be proposed by the Operations Group and approved by the Executive
216 Committee.
217

218 The Protocol Chair's role will focus on scientific aspects of a protocol. During protocol
219 development, the Protocol Chair will work with Coordinating Center staff to develop the
220 protocol.
221

222 The responsibilities of the Protocol Chair include, but are not limited to:

- 223 • Conduct protocol review calls with investigators at the commencement of a protocol
 - 224 • Lead in and encourage enrollment
 - 225 • Respond to protocol queries received from clinical sites
 - 226 • Respond to protocol treatment deviations by clinical sites
 - 227 • Consider modifications to the protocol, as necessary
 - 228 • In general chair writing committee for the primary manuscript from the study
 - 229 • Provide initial public presentation of main outcomes of the study
- 230 Quality control aspects will largely be the responsibility of the Operations Group, as they
231 are generally cross-protocol issues.
232

233 In general, an investigator should not serve as Protocol Chair for more than one major project at
234 a time.
235

236 A Protocol Development Committee will be formed for each protocol. This will include the
237 Protocol Chair, representatives of the Coordinating Center and, when appropriate, reading center
238 or other resource sites, the Network Chair, and other selected investigators and coordinators.
239 The activities of the Protocol Development Committees will be coordinated by the Coordinating
240 Center.

241
242 The responsibilities of the Protocol Development Committee include, but are not limited to:
243 • Development of the final protocol, informed consent form, data forms, study procedures, and
244 other study materials
245 • Development of certification requirements for site personnel
246 • Pilot testing of study forms and procedures prior to commencement of study participant
247 recruitment
248

249
250 Some protocols in development may require specialists from outside of the Network where
251 additional expertise is needed. The Operations Group will select specialists for such protocols.
252 The specialists will join the designated Protocol Development Committee(s) and will focus on
253 the non-retinal scientific aspects of the protocol(s).
254

255 **E. Committees**

256 **I. Executive Committee**

257 The standing members of the Executive Committee will include all members of the Operations
258 Group (listed in a separate section), each Protocol Chair, an NEI representative, a Reading
259 Center representative, a rotating site coordinator, and other Network investigators serving in
260 relevant positions, such as the Protocol Development investigator member. Up to two additional
261 rotating site investigators (not Protocol Chairs and not members of the Operations Group), may
262 be selected to join the Executive Committee. An investigator or coordinator from a site on
263 probation is not eligible for nomination to the Executive Committee. If a site is placed on
264 probation, any investigators or coordinators serving on the Executive Committee may be asked
265 to resign. The two site investigators and the site coordinator will be recommended by the
266 Operations Group to the Executive Committee for approval.
267

268 In general, Protocol Chairs will serve on the Executive Committee while their respective
269 protocol is active¹. Protocol Chairs generally will rotate off of the Executive Committee the
270 month after the final study visit of their respective protocol is completed, as recommended by the
271 Operations Group and approved by the Executive Committee. Depending upon the size of the
272 Executive Committee (i.e.; the number of Protocol Chairs), rotating site investigators may serve
273 a one-year term renewable up to two years. If multiple Protocol Chairs are serving on the
274 Executive Committee, then the rotating investigator members' one-year term will not be
275 renewed. If there are not enough Protocol Chairs, the rotating members' one-year term may be
276 renewed for an additional year. The site coordinator may serve a one-year term renewable up to
277 two years. The size of the Executive Committee should not exceed 20 members.
278

¹ A protocol is considered active until the final study visit has been completed.

279 One of the Protocol Chairs or site investigators not serving as a member of the Operations Group
280 will serve as the Chair of the Executive Committee for a one-year term. The individual serving
281 as Chair may remain as an ad hoc investigator member on the Executive Committee for one
282 additional year following the end of the Chair term year. The Executive Committee Chair will be
283 proposed by the Operations Group and approved by the Executive Committee. The selected
284 individual should already serve on the Executive Committee the year prior. The Executive
285 Committee Chair will be responsible for leading the monthly Executive Committee calls and will
286 work closely with the Network Chair relating to Operations Group decisions or discussions that
287 need to be discussed with the Executive Committee. Additional responsibilities may be added as
288 needed.

289
290 For issues requiring a vote, the Principal Investigator of the Coordinating Center will share a
291 single vote with any co-investigators of the Coordinating Center.

292
293 The Executive Committee has overall responsibility for providing scientific oversight of the
294 activities of the project. This Committee also formulates all policy decisions related to the
295 maintenance and conduct of the project.

296
297 Responsibilities of the Executive Committee include:

- 298 • Primary responsibility for the scientific oversight of the Network
- 299 • Provide input on issues related to the Network, including issues brought to the Committee by
300 the Operations Group
- 301 • Review monthly recruitment reports on active protocols across sites
- 302 • Develop and enforce Network policies
- 303 • Develop requirements for the participation of clinical sites and investigators and other site
304 personnel
- 305 • Select and prioritize protocols to be developed following recommendation of the Operations
306 Group and buy-in from investigators
- 307 • Select Network Chairs and Vice-Chair(s)
- 308 • Provide representatives to provide *ad hoc* review of the Coordinating Center and Network
309 Chair's Office. External members of such a review may be included.
- 310 • Select Protocol Chairs following recommendation of the Operations Group
- 311 • Review recommendations of the Operations Group of imaging needs and reading center(s)
312 for each protocol
- 313 • Review progress of imaging reading centers
- 314 • Review and approve final protocol and budget
- 315 • Consider and approve changes or modifications in protocol as may be necessary or desirable
- 316 • Advise and assist the Coordinating Center on operational matters

- 317 • Approve protocol dissemination plans including primary outcome manuscripts and
318 presentations
- 319 • Approve primary outcome and secondary outcome manuscripts
- 320 • Review and approve ancillary studies as recommended by the Operations Group
- 321 • Review and approve collaborations and funding, including unrestricted grants or gifts from
322 Industry or foundations
- 323 • Provide input to the Coordinating Center and Operations Center on Network budgets

324 The Executive Committee will convene by conference call once per month. Additional calls will
325 be held as needed. In general, two in-person Executive Committee meetings will be held each
326 year. Additional individuals (e.g., Protocol Chairs) may be asked to participate as indicated,
327 which may require pre-approval by the Executive Committee Chair.

328
329 **II. Steering Committees and Other Subcommittees**

330 Steering Committees and other subcommittees may be developed as needed for non-Network
331 areas where additional expertise is desired (e.g. genetics studies).

332
333 **III. Operations Group**

334 The Operations Group includes the current and past Network Chair(s), the Network Vice-
335 Chair(s), an NEI representative, and the Coordinating Center Principal Investigator and
336 Executive Director.

337 Specific functions of the Operations Group include:

338
339 **Develop and maintain a program of quality assurance in the study**

- 340 • Monitor the performance of all participating sites and central units
- 341 • Each site will be assigned to a team consisting of a Coordinating Center protocol monitor and
342 a Vice-Chair investigator who will be responsible for oversight of that site's performance,
343 including recruitment.
- 344 • Review quality assurance reports regarding Network performance, comprehensively on a
345 semiannual basis, and at any other times that issues arise
- 346 • Monitor adherence to protocols through review of collected data regarding performance and
347 site visits (accompanied by outside, independent, unconflicted consultants as needed)
- 348 • Review quality metrics across all sites and DRCRnet studies approximately twice per year at
349 in-person meetings
- 350 • Review site visit reports
- 351 • Report site performance to the Executive Committee as needed

352
353 **Protocol development**

- 354 • Review and approve study procedures of new protocols

- 355 • Conduct initial review of submitted protocol concepts from investigators and decide on
356 degree of merit and public health importance for presentation to investigators at the
357 semiannual Coordinator/Investigator meetings and recommendation to the Executive
358 Committee
- 359 • Select a Protocol Development Committee, if indicated, for each protocol to be developed
- 360 • Address imaging issues for Network protocols
- 361 • Submit recommendations to Executive Committee

362
363 **Oversight of active protocols**

- 364 • Provide input on protocol close-out procedures

365
366 **Manuscripts**

- 367 • Conduct initial review of manuscript ideas (with Manuscript Investigator Position) submitted
368 by investigators and decide on degree of merit for recommendation to the Coordinating
369 Center
- 370 • Prioritize manuscripts to be written, including review of manuscript ideas solicited from
371 investigators
- 372 • Select a writing committee for each manuscript

373
374 **Presentations**

- 375 • Plan for meeting presentations
- 376 • Review and approve abstracts prior to submission
- 377 • Review of posters and presentations

378
379 **Dissemination of study results**

- 380 • Develop plan for dissemination of study results as indicated

381
382 **New centers and investigators**

- 383 • Communicate with new centers, both before and after Network approval is granted

384

385 A weekly conference call of the Operations Group will be held. Additional calls will be held
386 with some or all of the Operations Group as deemed necessary by the Network Chair and
387 Coordinating Center Principal Investigator or Co-Investigator. In general, two in-person
388 Operations Group meetings will be held each year to review quality control, site monitoring, and
389 protocol ideas.

391 **IV. Manuscript Writing Committees**

392 The Operations Group is responsible for the selection of a writing committee for each
393 manuscript. The Operations Group provides oversight of manuscript writing, and at least one
394 member of the Operations Group will serve on the writing committee for each manuscript. In
395 general, each manuscript writing committee will consist of a lead author (or authors, if
396 applicable; for primary manuscripts, this is usually the protocol chair), a lead statistician, an
397 Operations Group member to provide oversight, and additional study group members
398 (investigators and coordinators) nominated by the Operations Group and based upon study
399 recruitment levels or particular expertise in the topic area of interest.

401 **V. Data and Safety Monitoring Committee (DSMC)**

402 The responsibility for reviewing the ethical conduct of the study and for monitoring the data for
403 evidence of adverse or beneficial treatment effects is assigned to the Data and Safety Monitoring
404 Committee (DSMC). The Data and Safety Monitoring Committee is advisory to the
405 Coordinating Center.

406
407 The members of the DSMC will be selected by the National Eye Institute, which will select one
408 of the members to serve as the Chair. The members will include individuals with expertise in
409 clinical trials, biostatistics, diabetic retinopathy, and diabetes as well as a layperson. The NEI
410 Project Officer will be considered an ex-officio nonvoting member.

411
412 Prior to the initiation of recruitment for a protocol, the DSMC must approve the study protocol,
413 including the informed consent procedure and form. Subsequent protocol changes that are
414 substantive must be approved by the DSMC prior to implementation. Minor changes that do not
415 impact patient safety or the assessment of efficacy do not require prior DSMC approval and will
416 be reported to the DSMC at its semi-annual meetings. At its discretion, the DSMC may
417 recommend to the Executive Committee that a protocol change be considered.

418
419 The DSMC will periodically review the progress of each protocol involving patient safety (at
420 least twice each year either at a meeting or via a conference call) and any other protocol they
421 deem would benefit from their monitoring. In conjunction with the Coordinating Center, the
422 Committee will determine specific plans for evaluating adverse effects and efficacy, including
423 deciding whether a formal interim analysis should be performed.

424
425 Recommendations made by this Committee relating to the protection of patient rights and/or
426 resulting from data analyses are forwarded to the National Eye Institute. For randomized clinical
427 trials, results are not available to the participating investigators involved in patient care until the
428 DSMC recommends that this information be released.

429
430 DSMC financial disclosures will be reviewed by two individuals with experience in financial
431 disclosures and financial conflicts who are independent of the Operations Center and
432 Coordinating Center investigators. These two individuals will provide advice to the Network
433 Chair and PI of the Coordinating Center or designate regarding financial conflicts and
434 management of financial conflicts following Network policies. It is anticipated that this external
435 advice usually or always will be followed. This external advice will be documented along with
436 any rationale if and when the advice is not followed.

437
438
439

Further details of the role of the DSMC appear in the DSMC Standard Operating Procedures.

440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485

DRCR.net Organizational Structure

